Creutzfeldt-Jakob disease

Creutzfeldt-Jakob disease (CJD) is a rare, progressive, and invariably fatal neurodegenerative disorder belonging to the transmissible spongiform encephalopathy (TSE) group. It is etiologically defined by the accumulation of misfolded prion protein (PrP^Sc) in the central nervous system, which induces conformational change in native cellular prion protein (PrP^C), leading to widespread neuronal dysfunction and death. The disease may arise sporadically, be inherited through mutations in the PRNP gene, or occur iatrogenically following exposure to contaminated human tissues or medical products. The name derives from the original description by German neurologists Hans Gerhard Creutzfeldt and Alfons Jakob in 1920, with formal classification established in the 1950s.

CJD manifests with rapidly progressive dementia, typically within months of symptom onset, accompanied by a range of neurological deficits. Early symptoms commonly include memory impairment, behavioral changes, poor coordination, visual or auditory disturbances, and anxiety or depression. As the disease advances, patients develop myoclonus (in ~90% of cases), aphasia, apraxia, cortical blindness, and severe motor dysfunction including ataxia and pyramidal/extrapyramidal signs. Several clinical variants have been described: classic CJD with global cognitive decline and myoclonus; pure cognitive variant resembling Alzheimer’s disease; ataxic variant with prominent gait instability; psychiatric variant with psychosis and delusions; visual/Heidenhain variant featuring cortical blindness and hallucinations; thalamic variant with insomnia and autonomic dysregulation; stroke-like variant with acute focal deficits; and others. Approximately 70% of patients die within one year of diagnosis.

CJD occurs globally but remains extremely rare, with an estimated incidence of 1–2 cases per million people annually in most developed countries. Sporadic CJD accounts for the majority (~87%) of cases, typically affecting individuals over age 60. Familial CJD, resulting from autosomal dominant PRNP mutations, comprises about 10–15% of cases and often presents earlier in life. Iatrogenic CJD, linked to exposure to contaminated human-derived products such as dural grafts, corneal transplants, or pituitary growth hormone, represents ~5% of cases and has declined markedly since the introduction of recombinant alternatives. Variant CJD (vCJD), associated with bovine spongiform encephalopathy (BSE) exposure through dietary ingestion, is exceedingly rare and primarily reported in the United Kingdom. Surveillance systems track case reports and deaths, though many cases remain undiagnosed ante-mortem.

The pathogenic agent in CJD is a misfolded prion protein, not a virus or bacterium, and it can transmit across individuals regardless of disease origin—sporadic, familial, or iatrogenic. Human-to-human transmission is possible via direct contact with infected neural tissue or contaminated surgical instruments, particularly in settings involving neurosurgical procedures or transplantation of neural or ocular tissues. Iatrogenic routes include administration of human-derived growth hormone, dural grafts, corneal transplants, and deep brain stimulation electrodes. There is no evidence of casual person-to-person transmission, nor of airborne or vector-borne spread. The variant form is believed to result from consumption of BSE-contaminated beef products, although this route has not been documented in other populations outside the UK outbreak period.

Primary risk groups include individuals aged >60 years (sporadic CJD), those with known PRNP mutations (familial CJD), and persons exposed to human-derived biological products (iatrogenic CJD), particularly those who received cadaveric dural grafts, corneal transplants, or pituitary-derived growth hormone before 1985. Individuals with prior exposure to BSE-contaminated food sources may be at risk for vCJD, though this remains exceptionally rare. No occupational or environmental exposure has been identified for sporadic cases. Genetic screening is recommended for first-degree relatives of familial CJD patients, and healthcare workers involved in neurosurgery or autopsy of suspected CJD cases require enhanced infection control precautions.

Prevention focuses on minimizing iatrogenic risk through strict biosafety protocols, use of recombinant rather than human-derived biological products, and decontamination of surgical instruments using validated methods (e.g., extended autoclaving at 134°C for 18 minutes or sodium hypochlorite treatment). Public health measures include exclusion of donors with neurological symptoms from blood and tissue donation programs, and monitoring of high-risk procedures. For familial cases, genetic counseling and testing are available for at-risk relatives where appropriate. No vaccine or prophylactic therapy exists for CJD, and no specific public health interventions target sporadic cases, given their unknown etiology and lack of identifiable exposure.

Surveillance for CJD requires active case detection through neurological and geriatric clinics, especially in patients presenting with rapid-onset dementia and myoclonus. Key indicators include unexplained neurological deterioration within weeks to months, presence of characteristic EEG patterns (e.g., periodic sharp wave complexes), elevated CSF 14-3-3 protein or neuron-specific enolase, and MRI findings such as cortical ribboning or basal ganglia hyperintensity. Reporting should follow national guidelines for notifiable diseases, with emphasis on distinguishing CJD from other rapidly progressive dementias. Given the disease’s near-universal fatality and long incubation periods in some forms, surveillance must also consider historical exposures and occupational histories when evaluating suspected cases.

1. 1 WHO Fact Sheet. Detail.
2. 2 WHO Q&A. News.
3. 3 Wikidata. Creutzfeldt-Jakob disease.
4. 4 Wikipedia. Creutzfeldt–Jakob disease - Wikipedia.

ICD-10

ICD-11

Total cases

2K

Peak month

2019-11

Coverage

2 reporting countries · 2000-01-01 → 2026-05-02